Royalty Pharma plc (RPRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Royalty Pharma plc (RPRX) closed at USD 58.99 on 2026-10-14, a change of +65.2 % over the past year, with a market capitalization of USD 34.45B.

Royalty Pharma plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Royalty Pharma plc key figures

Previous close

USD 58.99 (2026-10-14)

1-year change

+65.2 %

Market cap

USD 34.45B

Enterprise value

USD 37.63B

P/E ratio (trailing)

30.11

P/E ratio (forward)

10.28

EPS (trailing)

1.98

EPS (forward)

5.80

PEG ratio

1.37

Price to book

3.89

Revenue growth

16.5 %

Earnings growth

-46.3 %

Dividend per share (trailing)

0.91

Short ratio

3.89

Employees

100

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Royalty Pharma plc and compare it with other stocks.